Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression |
| June 25, 2021 | June 2021 Bond Updates |
|
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ -- Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that included challenging-to-treat patient populations Libtayo now approved by the European... |
| View more at: https://www.prnewswire.com:443/news-releases/libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-pd-l1-expression-301319980.html |